Featured news from NHIVNA
HIV-related news from NAM
Monoclonal antibodies show promise for HIV-positive people with limited treatment options
Liz Highleyman, 2017-02-22 12:00:00
A pair of long-acting monoclonal antibodies that
prevent HIV from entering human cells – ibalizumab and PRO 140 – may offer new
treatment options for people with highly resistant virus and limited treatment options,
researchers reported at the Conference on
Retroviruses and Opportunistic Infections (CROI 2017) last week in Seattle.
Ibalizumab infusions every two weeks in combination
with optimised background antiretroviral therapy (ART) demonstrated modest
antiviral activity, while PRO 140 administered by weekly injection maintained
viral suppression for more than two years in a majority of responders.